The extension by Roche was expected. An extremely low number of shares have been tendered, consistent with our view – and that of our stockholders – that Roche’s offer does not reflect Illumina’s unique leadership position, business performance and future prospects.Roche invested about 8 billion Swiss francs in R&D in 2011 and over 80,000 people were working for Roche in the world in 2011. Company shows interest in Illumina to expand the business of diagnostics.
Monday, February 27, 2012
Roche has extended tender offer for Illumina
Article first published as Rocheâ€™s Extension of Tender Offer and its Response by Illumina on Technorati.